




RealRate

# PHARMACEUTICAL 2011

Alnylam Pharmaceuticals INC  
Rank 27 of 31

Alnylam@20



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Alnylam Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Alnylam Pharmaceuticals INC compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Alnylam Pharmaceuticals INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 66% points.

The company's Economic Capital Ratio, given in the ranking table, is 227%, being 60% points below the market average of 287%.

| Input Variable                              | Value in<br>1000 USD |
|---------------------------------------------|----------------------|
| Assets, Current                             | 254,139              |
| Cost of Goods Sold                          | 0                    |
| Intangible Assets                           | 448                  |
| Liabilities, Current                        | 102,046              |
| Liabilities, Non-Current                    | 143                  |
| Other Assets                                | 120,389              |
| Other Compr. Net Income                     | -2.0                 |
| Other Expenses                              | 514                  |
| Other Liabilities                           | 132,843              |
| Other Net Income                            | 1,069                |
| Other Revenues                              | 100,041              |
| Property and Equipment                      | 18,289               |
| Research and Development                    | 106,384              |
| Selling, General and Administrative Expense | 37,727               |

| Output Variable             | Value in<br>1000 USD |
|-----------------------------|----------------------|
| Assets                      | 393,265              |
| Liabilities                 | 235,032              |
| Expenses                    | 144,625              |
| Revenues                    | 100,041              |
| Stockholders Equity         | 158,233              |
| Net Income                  | -43,515              |
| Comprehensive Net Income    | -43,516              |
| BaseVar                     | 437,017              |
| ECR before LimitedLiability | 96%                  |
| Economic Capital Ratio      | 227%                 |